282 related articles for article (PubMed ID: 2933492)
21. Phase II study of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin in advanced colorectal cancer. By the Gastrointestinal Tumor Study Group.
J Clin Oncol; 1984 Jul; 2(7):770-3. PubMed ID: 6234380
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
[TBL] [Abstract][Full Text] [Related]
23. Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Muggia FM; Camacho FJ; Kaplan BH; Green MD; Greenwald ES; Wernz JC; Engstrom PF
Cancer Treat Rep; 1987 Mar; 71(3):253-6. PubMed ID: 3815391
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Stridhar K; Reddy R; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Livingstone A
Int J Radiat Oncol Biol Phys; 1992; 22(3):511-4. PubMed ID: 1735689
[TBL] [Abstract][Full Text] [Related]
25. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
Mann GB; Hortobagyi GN; Buzdar AU; Yap HY; Valdivieso M
Cancer; 1985 Sep; 56(6):1320-4. PubMed ID: 4027872
[TBL] [Abstract][Full Text] [Related]
27. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
Petrelli N; Herrera L; Rustum Y; Burke P; Creaven P; Stulc J; Emrich LJ; Mittelman A
J Clin Oncol; 1987 Oct; 5(10):1559-65. PubMed ID: 2443619
[TBL] [Abstract][Full Text] [Related]
28. Biomodulation of Fluorouracil in colorectal cancer.
Ardalan B; Luis R; Jaime M; Franceschi D
Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Weiss GR; Ervin TJ; Meshad MW; Kufe DW
Cancer Treat Rep; 1982 Feb; 66(2):299-303. PubMed ID: 7055815
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.
Richards F; Case LD; White DR; Muss HB; Spurr CL; Jackson DV; Cooper MR; Zekan P; Cruz J; Stuart JJ
J Clin Oncol; 1986 Apr; 4(4):565-70. PubMed ID: 3514806
[TBL] [Abstract][Full Text] [Related]
31. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
32. 5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU.
Macdonald JS; Kisner DF; Smythe T; Woolley PV; Smith L; Schein PS
Cancer Treat Rep; 1976 Nov; 60(11):1597-600. PubMed ID: 1021233
[TBL] [Abstract][Full Text] [Related]
33. A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
Windschitl HE; O'Connell MJ; Wieand HS; Krook JE; Rubin J; Moertel CG; Kugler JW; Pfeifle DM; Goldberg RM; Laurie JA
Cancer; 1990 Sep; 66(5):853-6. PubMed ID: 2201430
[TBL] [Abstract][Full Text] [Related]
34. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
Carroll DS; Gralla RJ; Kemeny NE
Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
[No Abstract] [Full Text] [Related]
35. [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Togni P; Sessa C; Varini M; Cavalli F
Schweiz Med Wochenschr; 1982 Jun; 112(26):930-3. PubMed ID: 6214002
[TBL] [Abstract][Full Text] [Related]
36. Pilot study of PALA and 5-FU in patients with advanced cancer.
O'Connell MJ; Powis G; Rubin J; Moertel CG
Cancer Treat Rep; 1982 Jan; 66(1):77-80. PubMed ID: 7053270
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of combination therapy with PALA and 5-FU.
Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
[TBL] [Abstract][Full Text] [Related]
38. Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma.
Weltz MD; Perry DJ; Blom J; Butler WM
J Clin Oncol; 1983 Feb; 1(2):135-7. PubMed ID: 6230421
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF
J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507
[TBL] [Abstract][Full Text] [Related]
40. Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Chun H; Martin D; Young C
Cancer Treat Rep; 1985 Feb; 69(2):179-84. PubMed ID: 3971391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
